AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03797807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MINST
Description: A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
Study NCT02123199 — intervention group
Intervention type: DRUG
Intervention: Indacaterol (Onbrez®) /QAB149
Study NCT02142686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filling pressure 80
Description: After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
Study NCT02142686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filling pressure 50
Description: After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
Study NCT02142686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filling pressure 30
Description: After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
Study NCT03791866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Enteral nutrition
Study NCT03791866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Enteral nutrition
Study NCT02072291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: PO Nifedipine 5mg single dose
Study NCT02072291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Description: PO Nifedipine 5mg single dose
Study NCT02142166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biomarker in serum, liquor, micro-dialysate
Description: Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
Study NCT02142166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biomarker in serum and in liquor
Description: Single analysis of biomarker in serum and liquor
Study NCT03797807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MINST
Description: A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
Study NCT03797807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIST
Description: A minimally invasive surgical treatment protocol, named MIST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
Study NCT03797807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: GTI subgroup (Geometrical/Thermal Imaging)
Description: Geometrical/Thermal Imaging
Study NCT01332487 — intervention group
Intervention type: DRUG
Intervention: 5ARI + AB
Description: 5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
Study NCT02380339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psych-Educational session and virtual reality
Description: Psych-Educational session and virtual reality
Study NCT02380339 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psych-Educational and BF sessions
Description: Psych-Educational and BF sessions
Study NCT03426995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
Study NCT03426995 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LPS
Description: LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
Study NCT01170728 — intervention group
Intervention type: DEVICE
Intervention: Coloplast Virtue® Male Sling
Description: The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
Study NCT01414569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Singe dose preoperatively in 100 ml saline intravenously
Study NCT01414569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Singe dose preoperatively in 100 ml saline intravenously
Study NCT01414569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Singe dose preoperatively in 100 ml saline intravenously
Study NCT05156580 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention
Study NCT01095588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg Avanafil
Description: 2 X 100mg tablets avanafil
Study NCT01095588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets
Study NCT01790334 — intervention group
Intervention type: OTHER
Intervention: Ultrasonography
Study NCT04582032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen (KETAVEL 50 mg/2 ml)
Description: intravenous dexketoprofen (KETAVEL 50 mg/2 ml)
Study NCT04582032 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saline (Isotonic Saline Solution 0.9% )
Description: intravenous 2 ml of saline
Study NCT03426995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
Study NCT01605851 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Closure, Foramen Ovale
Study NCT01059656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
Study NCT03426995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cantharidin
Description: This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
Study NCT02632045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg injection
Study NCT02632045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600 mg capsule (3x 200 mg capsules)
Study NCT02570815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
Study NCT02588027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
Study NCT02588027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmacy formulated placebo
Study NCT03832907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM - Continues Glucose Monitoring sensor system
Description: A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
Study NCT03832907 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC BG - Point-of-Care Blood Glucose monitoring
Description: Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
Study NCT03790475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offering a choice for colorectal cancer screening
Description: Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
Study NCT03790475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offering an alternative colorectal cancer screening method
Description: Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
Study NCT04555772 — intervention group
Intervention type: OTHER
Intervention: factors evaluation
Description: They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
Study NCT00812968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
Study NCT03740126 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole body 18F-FDG PET/CT
Description: In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
Study NCT03754400 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
Study NCT03754400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Antibiotics, nutrition and supportive treatment
Study NCT03754400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Antibiotics, nutrition and supportive treatment
Study NCT01193478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, 3 mg once daily for 3 days
Study NCT01193478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: tablet, oral, once daily for 3 days
Study NCT01193478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, 10 mg once daily for 3 days
Study NCT00857155 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clopidogrel withdraw prior to CABG
Description: Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
Study NCT00489866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
Study NCT00489866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active drug.
Study NCT01193478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, 30 mg once daily for 3 days
Study NCT01193478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, up to 90 mg once daily for 3 days
Study NCT04692974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone application and smart watch
Description: Mobile phone application prompts
Study NCT05463393 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/
Description: The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
Study NCT05463393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/
Description: The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
Study NCT00975000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Possible sequential doses are 30, 60, 90, 120, and 180 mg.
Study NCT00975000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally following the same dosing regimen as the experimental arm.
Study NCT02047929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Shared Decision Making (SDM) Toolkit
Description: A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
Study NCT01869959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2405319
Description: Administered SC
Study NCT01869959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02903849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drafting Motivational Messages
Description: Write down three motivating messages
Study NCT02903849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Reminders
Description: Receive standard reminders at three points during the challenge
Study NCT02903849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Reminders
Description: Receive reminders containing the messages they leave themselves at three points during the challenge
Study NCT03686085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
Study NCT03686085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vaginal tablet
Description: 1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
Study NCT01388036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmolol
Description: consecutive infusions of esmolol and normal saline (placebo)
Study NCT01717300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Description: 100 mg tablet, oral, once daily for 24 weeks
Study NCT01717300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for anacetrapib 100 mg
Description: Placebo tablet, orally, once daily for 24 weeks
Study NCT01717300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for anacetrapib 100 mg
Description: Placebo tablet, orally, once daily for 24 weeks
Study NCT01717300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib 25 mg
Description: 25 mg tablet, oral, once daily for 24 weeks
Study NCT01717300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for anacetrapib 25 mg
Description: Placebo tablet, orally, once daily for 24 weeks
Study NCT01717300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for anacetrapib 25 mg
Description: Placebo tablet, orally, once daily for 24 weeks
Study NCT03504501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: oral application prior to transcranial magnetic stimulation intervention
Study NCT03504501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: oral application prior to transcranial magnetic stimulation intervention
Study NCT01322061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
Study NCT01322061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
Study NCT02020356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase.
Study NCT02020356 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
Study NCT01153971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1
Study NCT02156570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin
Description: Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg \<75kg, 1200mg >/= 75 kg) Treatment will be for 6 weeks in all participants.
Study NCT00759369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water prescription
Description: Water prescription in 12 to 16 equally divided doses
Study NCT00795886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAPAMYCIN
Description: Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
Study NCT04901182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
Description: the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
Study NCT04901182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
Description: the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
Study NCT05620186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PROSPECT
Description: PROficiency Based StePwise Endovascular Curricular Training
Study NCT05577819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-pyrophosphate Scintigraphy
Description: Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer